ATE378042T1 - Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln - Google Patents

Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln

Info

Publication number
ATE378042T1
ATE378042T1 AT05718387T AT05718387T ATE378042T1 AT E378042 T1 ATE378042 T1 AT E378042T1 AT 05718387 T AT05718387 T AT 05718387T AT 05718387 T AT05718387 T AT 05718387T AT E378042 T1 ATE378042 T1 AT E378042T1
Authority
AT
Austria
Prior art keywords
multiparticles
brushing
taste
discovered
drugs
Prior art date
Application number
AT05718387T
Other languages
English (en)
Inventor
Leah Eizabeth Appel
Richard Frank Falk Iii
Dwayne Thomas Friesen
Sanjay Konagurthu
Edward Dennis Lachapelle
Joseph Peter Reo
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE378042T1 publication Critical patent/ATE378042T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05718387T 2004-04-12 2005-04-06 Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln ATE378042T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56159504P 2004-04-12 2004-04-12

Publications (1)

Publication Number Publication Date
ATE378042T1 true ATE378042T1 (de) 2007-11-15

Family

ID=35125594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05718387T ATE378042T1 (de) 2004-04-12 2005-04-06 Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln

Country Status (9)

Country Link
US (1) US8236349B2 (de)
EP (1) EP1737433B1 (de)
JP (1) JP2007532623A (de)
AT (1) ATE378042T1 (de)
BR (1) BRPI0509276A (de)
CA (1) CA2561855A1 (de)
DE (1) DE602005003343T2 (de)
MX (1) MXPA06011765A (de)
WO (1) WO2005097064A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ709754A (en) * 2004-10-21 2017-02-24 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1810668A1 (de) * 2006-01-23 2007-07-25 LEK Pharmaceuticals D.D. Beschichtete Arzneizubereitungen enthaltend Tolterodintartrat
US8716200B2 (en) 2006-09-13 2014-05-06 Ecolab Usa Inc. Conveyor lubricants including emulsion of a lipophilic compound and an emulsifier and/or an anionic surfactant and methods employing them
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
WO2009061465A1 (en) * 2007-11-06 2009-05-14 Teva Pharmaceutical Industries Ltd. Chewable formulations
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.
US20110150993A1 (en) * 2009-12-22 2011-06-23 Fmc Corporation Fine Particle Croscarmellose and Uses Thereof
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
US20170266115A1 (en) 2016-03-15 2017-09-21 Acer Therapeutics Inc. Palatable compositions including sodium phenylbutyrate and uses thereof
CA3033973A1 (en) * 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release of fat-soluble actives
JP7182550B2 (ja) 2017-08-21 2022-12-02 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
JP2020015690A (ja) * 2018-07-25 2020-01-30 ニプロ株式会社 レボセチリジン含有錠剤
JP7271869B2 (ja) * 2018-07-25 2023-05-12 ニプロ株式会社 レボセチリジン含有錠剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1266827A (en) * 1984-06-20 1990-03-20 Merck & Co., Inc. Controlled porosity osmotic pump
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NZ226179A (en) * 1987-09-24 1991-04-26 Merck & Co Inc Controlled porosity osmotic pump for sustained release of pharmaceutical agents
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
DE3838094A1 (de) * 1988-11-10 1990-05-17 Nordmark Arzneimittel Gmbh Feste pharmazeutische retardform
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
ES2097155T3 (es) 1989-10-02 1997-04-01 Cima Labs Inc Forma de dosificacion efervescente y metodo de administracion.
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5336433A (en) * 1992-06-08 1994-08-09 Eka Nobel Ab Bleaching agent
WO1994001093A1 (en) * 1992-07-09 1994-01-20 Merck & Co., Inc. Controlled porosity osmotic enalapril pump
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
AU7407194A (en) 1993-08-03 1995-02-28 Warner-Lambert Company Pleasant tasting effervescent cold/allergy medications
US5518801A (en) 1993-08-03 1996-05-21 The Procter & Gamble Company Web materials exhibiting elastic-like behavior
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
DE19809719A1 (de) * 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
US6723358B1 (en) * 1998-03-23 2004-04-20 General Mills, Inc. Encapsulation of components into edible products
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6482823B1 (en) * 1999-07-09 2002-11-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical liquid formulations
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
CA2393231A1 (en) * 1999-12-06 2001-06-07 Edward Mendell Co., Inc. Pharmaceutical superdisintegrant
AU2001231018A1 (en) 2000-01-19 2001-07-31 Pharmaceutical Discovery Corporation Multi-spike release formulation for drug delivery
DE60128215T2 (de) * 2000-04-20 2008-01-10 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
CA2406696C (en) * 2000-04-26 2009-06-30 Elan Pharma International Limited Apparatus for sanitary wet milling
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects

Also Published As

Publication number Publication date
CA2561855A1 (en) 2005-10-20
BRPI0509276A (pt) 2007-09-04
DE602005003343T2 (de) 2008-09-11
JP2007532623A (ja) 2007-11-15
WO2005097064A2 (en) 2005-10-20
EP1737433B1 (de) 2007-11-14
US20070196483A1 (en) 2007-08-23
DE602005003343D1 (de) 2007-12-27
WO2005097064A3 (en) 2006-08-03
MXPA06011765A (es) 2006-12-15
EP1737433A2 (de) 2007-01-03
US8236349B2 (en) 2012-08-07

Similar Documents

Publication Publication Date Title
ATE378042T1 (de) Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
UY27720A1 (es) Aroilpiridinonas monocíclicas,
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
ITFI20050042A1 (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
MX2010001574A (es) Ligandos del receptor cannabinoide.
ATE538125T1 (de) Neue 2-azaindol-derivate, deren herstellung und pharmazeutische verwendung als kinase-inhibitoren
SG152257A1 (en) Topical preparation containing ambroxol
SE0401342D0 (sv) Therapeutic compounds
ATE490967T1 (de) 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
DE602005011818D1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
NO20091628L (no) Kombinasjonsmedikament

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties